Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Local Disease Clear all

Conditions: Opioid Tolerance, Opioid Naive, Opioid Exposure
Interventions: Ropivacaine injection; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain, Postoperative
Interventions: Liposomal Injection Bupivacaine (Exparel), Standard bupivicaine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Post Operative Pain, Appendicitis
Interventions: Pre Incisional Local Anesthetic, Pre-Incisional Saline, Post-Closure Local Anesthetic, Post-Closure Saline; Drug · Other
Lead sponsor: Valley Anesthesiology Consultants; Other
Eligibility: 9 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions: Enoxaparin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 100 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Hyperpolarized 129-Xenon gas, MRI; Drug · Device
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina • Madison, Wisconsin

Conditions: Pregnancy
Interventions: Bupivacaine, Sufentanil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment, Recurrent Bladder Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Uterine Sarcoma, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage II Bladder Cancer, Stage II Renal Cell Cancer, Stage II Urethral Cancer, Stage IIA Cervical Cancer, Stage IIA Colon Cancer, Stage IIA Gastric Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIA Uterine Sarcoma, Stage IIB Cervical Cancer, Stage IIB Colon Cancer, Stage IIB Gastric Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIB Uterine Sarcoma, Stage IIC Colon Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIC Rectal Cancer, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage III Urethral Cancer, Stage IIIA Cervical Cancer, Stage IIIA Colon Cancer, Stage IIIA Gastric Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Uterine Sarcoma, Stage IIIB Cervical Cancer, Stage IIIB Colon Cancer, Stage IIIB Gastric Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Uterine Sarcoma, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Uterine Sarcoma, Stage IV Bladder Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Urethral Cancer, Stage IVA Cervical Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Uterine Sarcoma, Stage IVB Cervical Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Stage IVB Uterine Sarcoma, Ureter Cancer, Stage IIA Lung Carcinoma, Stage IIB Lung Carcinoma, Stage IIIA Lung Carcinoma, Stage IIIB Lung Carcinoma
Interventions: educational intervention, telephone-based intervention, quality-of-life assessment, questionnaire administration; Other · Behavioral · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anesthesia, Local
Interventions: Ropivacaine 0.75%, Ropivacaine 0.75% + 300 mcg Buprenorphine, Ropivacaine 0.75% + 75 mcg clonidine, Ropivacaine 0.75% + 8 mg dexamethasone; Drug
Lead sponsor: Melinda Seering; Other
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions: Medical Grade Oxygen; Drug
Lead sponsor: Hal C Charles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Local Anesthetics
Interventions: Lidocaine, normal saline, alkalinized lidocaine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 19 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Microtia, Congenital, Microtia, Anesthesia, Local, Anesthesia
Interventions: Erector Spinae Plane Block; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Anesthesia, Conduction, Osteoarthritis, Hip
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Bermuda Run, North Carolina

Conditions: Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions: Mepivacaine, Perifemoral Injection of Local Anesthetic, Saline; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Musculoskeletal Diseases
Interventions: ACE-083; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Immune System and Related Disorders
Interventions: Ibuprofen, Compound Exercise of Push-ups, oral placebo; Drug · Behavioral
Lead sponsor: Womack Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Bragg, North Carolina

Conditions: Knee Arthropathy
Interventions: ACB + IPACK block with injection of local anesthetic, ACB + IPACK block without injection; Other
Lead sponsor: University of Louisville; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Premature Birth
Interventions: Not listed
Lead sponsor: Aaron Hamvas; Other
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Obesity
Interventions: Somatostatin, Epinephrine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post Operative Pain (Post Laparoscopic Hernia Repair)
Interventions: 0.5% Bupivicaine; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Breast Cancer
Interventions: Focused Microwave Thermotherapy, Chemotherapy (control); Device · Drug
Lead sponsor: Medifocus, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions: DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8; Genetic · Other · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Complex Regional Pain Syndromes
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Peritoneal Neoplasms, Stomach Neoplasms
Interventions: CHPP with cisplatin; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Opioid Induced Loss of Local Anesthetic Potency in Patients Undergoing Total Knee Arthroplasty

Exparel vs. Standard Bupivicaine for Abdominoplasty

Evaluation of Local Anesthetic at Incision Site

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

PIEB vs CEI for Labor Analgesia: An MLAC Study

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block

Imaging Lung Function Using Oxygen Enhanced MRI

Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.

Rib Microtia and the Erector Spinae Plane (ESP) Block

Pain and Sensation After Regional Anesthesia - Pilot Study

Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

Phase 1 Study of ACE-083 in Healthy Subjects

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

ACB + IPACK Block With or Without Local Infiltration in RA-TKA

Local Version of the Multi-center PREVENT Study Evaluating Cardio-respiratory Instability in Premature Infants

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Effects of Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Role of the Gut Microbiome in Complex Regional Pain Syndrome

Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis